ABCELLERA BIOLOGICS (F:8QQ) — Market Cap & Net Worth
Market Cap & Net Worth: ABCELLERA BIOLOGICS (8QQ)
ABCELLERA BIOLOGICS (F:8QQ) has a market capitalization of $1.27 Billion (€1.09 Billion) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #7793 globally and #1061 in its home market, demonstrating a 2.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ABCELLERA BIOLOGICS's stock price €5.18 by its total outstanding shares 305264947 (305.26 Million). See ABCELLERA BIOLOGICS capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
ABCELLERA BIOLOGICS Market Cap History: 2020 to 2026
ABCELLERA BIOLOGICS's market capitalization history from 2020 to 2026. Data shows change from $11.82 Billion to $1.85 Billion (-29.37% CAGR).
ABCELLERA BIOLOGICS Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ABCELLERA BIOLOGICS's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
13.68x
ABCELLERA BIOLOGICS's market cap is 13.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $4.28 Billion | $375.20 Million | $153.46 Million | 11.41x | 27.91x |
| 2022 | $3.33 Billion | $485.42 Million | $158.52 Million | 6.87x | 21.03x |
| 2023 | $1.90 Billion | $38.02 Million | -$146.40 Million | 49.95x | N/A |
| 2024 | $1.01 Billion | $28.83 Million | -$162.86 Million | 34.97x | N/A |
| 2025 | $1.03 Billion | $75.13 Million | -$146.41 Million | 13.68x | N/A |
Competitor Companies of 8QQ by Market Capitalization
Companies near ABCELLERA BIOLOGICS in the global market cap rankings as of August 4, 2026.
Key companies related to ABCELLERA BIOLOGICS by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
ABCELLERA BIOLOGICS Historical Marketcap From 2020 to 2026
Between 2020 and today, ABCELLERA BIOLOGICS's market cap moved from $11.82 Billion to $ 1.85 Billion, with a yearly change of -29.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.85 Billion | +79.86% |
| 2025 | €1.03 Billion | +1.95% |
| 2024 | €1.01 Billion | -46.92% |
| 2023 | €1.90 Billion | -43.03% |
| 2022 | €3.33 Billion | -22.16% |
| 2021 | €4.28 Billion | -63.77% |
| 2020 | €11.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of ABCELLERA BIOLOGICS was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.27 Billion USD |
| MoneyControl | $1.27 Billion USD |
| MarketWatch | $1.27 Billion USD |
| marketcap.company | $1.27 Billion USD |
| Reuters | $1.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ABCELLERA BIOLOGICS
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more